Radiopharmaceutical Selection & Chemistry Development
Radiopharmaceutical Candidate Selection
Whether it is the development of a radiotracer to visualise and quantify tissue biology or a radiolabelled candidate as a potential therapeutic, a well-defined set of steps have to be taken to identify the right molecule, the right isotope and the right process in order to maximise the chance of success in translating a candidate from initial non-clinical studies through to clinical use. CITRAS combines strength across all areas and can support:
- Novel radiopharmaceutical development options and management
- Library screening
- Pharmacology
- Radiolabelling assessment
- Radioisotope selection
Please get in touch to learn more about our services
Radiochemistry Development
Process optimisation, product stability and specification are key activities to be completed in order to proceed to clinical use. CITRAS can help make sure these are optimised, reducing the risk of avoidable delays during regulatory IND or IMP submissions. Equally, despite best efforts, things can go wrong. The ability to objectively review issues and implement appropriate measures to avoid repeat reoccurrence is key to successful operational delivery. CITRAS can provide support for the following areas:
- Radiochemistry optimisation for clinical translation
- Synthesis platform advice
- Supply of precursor (API) and reference standard
- Product formulation
- Product specification
- Impurities
- Product stability
- Trouble shooting and root cause analysis
Please get in touch to learn more about our services
Our Services
Discuss Your Radiopharmaceutical Programme with Our Senior Team
Independent expertise in radiochemistry, imaging and regulatory strategy - tailored to your development stage.